Clinical Experiences with Dopamine Neuron Replacement in Parkinson's Disease: What Is the Future?

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Lindvall, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cell therapy; Dopamine neurons; Parkinson's disease; Transplantation

Indexed keywords

EID: 84918918483     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0033     Document Type: Chapter

References (60)

1. Kleiner-Fisman G*Herzog J*Fisman DN*et al. Subthalamic deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(suppl 14): S290-S304.
2. Lindvall O*Brundin P*Widner H*et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247:574-577.
3. Lindvall O*Sawle G*Widner H*et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol. 1994;35:172-180.
4. Sawle GV*Bloomfield PM*Björklund A*et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol. 1992;31:166-173.
5. Peschanski M*Defer G*N'Guyen JP*et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain. 1994;117: 487-499.
6. Freeman TB*Olanow CW*Hauser RA*et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol. 1995;38:379-388.
7. Remy P*Samson Y*Hantraye P*et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol. 1995;38:580-588.
8. Wenning GK*Odin P*Morrish P*et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol. 1997;42:95-107.
9. Hagell P*Schrag A*Piccini P*et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999;122:1121-1132.
10. Hauser RA*Freeman TB*Snow BJ*et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999;56:179-187.
11. Brundin P*Pogarell O*Hagell P*et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000;123: 1380-1390.
12. Freed CR*Greene PE*Breeze RE*et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710-719.
13. Olanow CW*Goetz CG*Kordower JH*et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403-414.
14. Cochen V*Ribeiro MJ*Nguyen JP*et al. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord. 2003;18:928-932.
15. Mendez I*Dagher A*Hong M*et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg. 2002;96:589-596.
16. Mendez I*Sanchez-Pernaute R*Cooper O*et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128:1498-1510.
17. Kordower JH*Freeman TB*Snow BJ*et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 1995;332:1118-1124.
18. Kordower JH*Rosenstein JM*Collier TJ*et al. Functional fetal nigral grafts in a patient with Parkinson's disease: (p.487) chemoanatomic*ultrastructural*and metabolic studies. J Comp Neurol. 1996;370:203-230.
19. Kordower JH*Freeman TB*Chen EY*et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord. 1998;13:383-393.
20. Kordower JH*Chu Y*Hauser RA*et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14:504-506.
21. Li J-Y*Englund E*Holton JL*et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501-503.
22. Mendez I*Vinuela A*Astradsson A*et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008;14:507-509.
23. Piccini P*Brooks DJ*Björklund A*et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 1999;2:1137-1140.
24. Piccini P*Pavese N*Hagell P*et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain. 2005;128:2977-2986.
25. Piccini P*Lindvall O*Björklund A*et al. Delayed recovery of movementrelated cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000;48: 689-695.
26. Lindvall O*Widner H*Rehncrona S*et al. Transplantation of fetal dopamine neurons in Parkinson's disease: 1-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992;31:155-165.
27. Defer GL*Geny C*Ricolfi F*et al. Long-term outcome of unilaterally transplanted parkinsonian patients: I. Clinical approach. Brain. 1996;119:41-50.
28. Mendez I*Dagher A*Hong M*et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. J Neurosurg. 2000;92:863-869.
29. Hagell P*Cenci MA. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull. 2005;68:4-15.
30. Hagell P*Piccini P*Björklund A*et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 2002;5:627-628.
31. Graff-Radford J*Foote KD*Rodriguez RL*et al. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch Neurol. 2006;63:1181-1184.
32. Herzog J*Pogarell O*Pinsker MO*et al. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov Disord. 2008;23:1293-1296.
33. Ma Y*Feigin A*Dhawan V*et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol. 2002;52:628-634.
34. Maries E*Kordower JH*Chu Y*et al. Focal*not widespread*grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006;21:165-180.
35. Carta M*Carlsson T*Kirik D*Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819-1833.
36. Carlsson T*Carta M*Winkler C*et al. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 2007;27:8011-8022.
37. Soderstrom KE*Meredith G*Freeman TB*et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol Dis. 2008;32:229-242.
38. Lane EL*Soulet D*Vercammen L*et al. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol Dis. 2008;32:220-228.
39. Brundin P*Li J-Y*Holton JL*et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci. 2008;9:741-745.
40. Lindvall O*Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res. 2000;127: 299-320.
41. Isacson O*Bjorklund LM*Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol. 2003;53(suppl 3):S135-S146.
42. Hagell P*Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson's disease. J Neuropathol Exp Neurol. 2001;60:741-752.
43. Wernig M*Zhao J-P*Pruszak J*et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA. 2008;105:5856-5861.
44. Tabar V*Tomishima M*Panagiotakos G*et al. Therapeutic cloning in individual parkinsonian mice. Nat Med. 2008;14: 379-381.
45. Behrstock S*Ebert A*McHugh J*et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 2006;13: 379-388.
46. Marks WJ Jr*Ostrem JL*Verhagen L*et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2- neurturin) to patients with idiopathic Parkinson's disease: an open-label*phase I trial. Lancet Neurol. 2008;7: 400-408.
47. Björklund LM. Sánchez-Pernaute R*Chung S*et al. Embryonic cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002;99:2344-2349.
48. Cho MS*Lee Y-E*Kim JY*et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA. 2008;105: 3392-3397.
49. Dezawa M*Kanno H*Hoshino M*et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004;113: 1701-1710.
50. Kawasaki H*Mizuseki K*Nishikawa S*et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28:31-40.
51. Kawasaki H*Suemori H*Mizuseki K*et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell- derived inducing activity. Proc Natl Acad Sci USA. 2002;99:1580-1585.
52. Kim JH*Auerbach JM*Rodriguez-Gomez JA*et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50-56.
53. O'Keeffe FE*Scott SA*Tyers P*et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain. 2008;131: 630-641.
54. Parish CL*Castelo-Branco G*Rawal N*et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest. 2008;118: 149-160.
55. Rodriguez-Gomez JA*Lu J-Q*Velasco I*et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells. 2007;25:918-928.
56. Roy NS*Cleren C*Singh SK*et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomeraseimmortalized midbrain astrocytes. Nat Med. 2006;12:1259-1268.
57. Sanchez-Pernaute R*Studer L*Bankiewicz KS*et al. In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res. 2001;65:284-288.
58. Shim J-W*Park C-H*Bae Y-C*et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells. 2007;25: 1252-1262.
59. Studer L*Tabar V*McKay RDG. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci. 1998;1:290-295.
60. Takagi Y*Takahashi J*Saiki H*et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest. 2005;115:102-109.